For patients with COPD, budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol.

Metered-dose inhaler budesonide-glycopyrrolate-formoterol (Breztri Aerosphere) was associated with a higher risk of a first moderate or severe COPD exacerbation (HR 1.09, 95% CI 1.04-1.14 ...

A study compares budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol, revealing insights on COPD ...

AstraZeneca may mount a challenge to GlaxoSmithKline’s three-in-one inhaler for chronic obstructive pulmonary disease (COPD) after a late-stage trial success. AZ’s single inhaler, PT010 ...

A further 500 were given the triple combination but in two inhalers. COPD is term used to describe a number of progressive lung diseases such as emphysema. The main cause is smoking, although the ...

Inhalers are crucial tools for people with lung conditions such as asthma or chronic obstructive pulmonary disease (COPD). Some people ... inhaler canister, tt's best to hold on to the packaging ...

GSK, leading the COPD market with its Trelegy ... therapies should not overshadow choosing the best therapy for each patient. "Are dry powder inhalers the key to sustainable respiratory care?" ...

Inhalers may be prescribed to people who have a variety of health conditions both chronic and acute, including asthma, chronic obstructive pulmonary disease (COPD), and bronchitis. If you're new ...

Qualcomm and its rival Propeller are emerging as the tech companies to partner with in the development of smart inhalers. Virtually all the companies active in the asthma and COPD markets have ...

DOI: 10.1136/bmj-2024-080409 Meng-Ting Wang et al, Environmentally friendly inhaler regimens for COPD, BMJ (2024). DOI: 10.1136/bmj.q2825 ...

a once-daily dry powder inhaler for treatment of COPD in routine clinical practice in a new-user, 1:1 propensity score-matched cohort study. The study included 20,388 propensity score-matched ...